Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial, the company on Thursday announced through an exchange filing.
Plerixafor is used by patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. The drug will be manufactured at the group’s injectable manufacturing facility of Zydus Lifesciences Ltd. (Alidac) at SEZ, Ahmedabad (India).
Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial had annual sales of USD 210 million in the United States.
The group now has 374 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences Ltd Shares
The shares of Zydus Lifesciences Ltd on Thursday at 1:28 pm IST were at ₹654.40, up by 5.08 percent.
